What is the recommended treatment for a urinary tract infection caused by a carbapenemase‑producing organism?

Treatment for Urinary Tract Infection Caused by Carbapenemase-Producing Organisms

For UTIs caused by carbapenemase-producing Enterobacterales (CPE), first-line treatment should be ceftazidime-avibactam 2.5 g IV q8h, meropenem-vaborbactam 4 g IV q8h, or imipenem-cilastatin-relebactam 1.25 g IV q6h for 5-7 days. 1

Treatment Algorithm Based on UTI Severity

For Simple Cystitis (Uncomplicated Lower UTI)

• Single-dose aminoglycoside (gentamicin 5-7 mg/kg IV or amikacin 15 mg/kg IV) is recommended as first-line therapy 1
• This approach achieves urinary concentrations 25-100 fold higher than plasma levels and maintains therapeutic levels for days after a single dose 1

For Complicated UTI/Pyelonephritis

Preferred regimens (choose based on availability and susceptibility):

1. Ceftazidime-avibactam 2.5 g IV q8h (weak recommendation, very low quality evidence) 1

   • Active against KPC and OXA-48-like carbapenemases
   • NOT active against metallo-β-lactamases (NDM, VIM, IMP)

2. Meropenem-vaborbactam 4 g IV q8h (weak recommendation, low quality evidence) 1

   • Demonstrated non-inferiority to best available therapy in TANGO-II trial
   • Active against KPC-producing strains

3. Imipenem-cilastatin-relebactam 1.25 g IV q6h (weak recommendation, low quality evidence) 1

   • Active against KPC-producing strains and class C cephalosporinases
   • NOT active against metallo-β-lactamases or CRAB

4. Plazomicin 15 mg/kg IV q12h (weak recommendation, very low quality evidence) 1

   • Novel aminoglycoside stable against aminoglycoside-modifying enzymes
   • Active against KPC and OXA-48 producers, variable activity against MBL-producing strains

Duration: 5-7 days for complicated UTI 1

Critical Implementation Considerations

Obtain Infectious Disease Consultation

Strongly recommended for all multidrug-resistant organism infections (strong recommendation, low quality evidence) 1

Determine Carbapenemase Type

The specific carbapenemase produced determines optimal therapy:

• KPC or OXA-48-like producers: Use ceftazidime-avibactam, meropenem-vaborbactam, or imipenem-cilastatin-relebactam 1, 2
• Metallo-β-lactamases (NDM, VIM, IMP): Novel β-lactam/β-lactamase inhibitors are NOT effective; consider ceftazidime-avibactam PLUS aztreonam, or cefiderocol if susceptible 2

Resistance Emergence Warning

Critical pitfall: Ceftazidime-avibactam resistance can emerge during therapy, particularly with KPC-3 producers 1. A "see-saw effect" occurs where ceftazidime-avibactam MICs rise while meropenem MICs paradoxically decrease to susceptible range. The British Society for Antimicrobial Chemotherapy recommends considering combination therapy (ceftazidime-avibactam plus carbapenem or colistin) for KPC-3 producers, though the guideline panel notes insufficient evidence for this approach in UTI 1.

Alternative Regimens When First-Line Options Unavailable

Polymyxin-Based Combination Therapy

• Colistin 5 mg CBA/kg IV loading dose, then 2.5 mg CBA × (1.5 × CrCl + 30) IV q12h
• Must be combined with another agent based on susceptibility testing (tigecycline or meropenem) 1
• Avoid if possible due to nephrotoxicity and lack of robust clinical data 2

Fosfomycin

• Consider for susceptible isolates or when synergy testing demonstrates benefit 3
• Particularly useful for oral step-down therapy after initial IV treatment 4
• Avoid in patients with hypernatremia, cardiac or renal insufficiency 3

Special Populations

Pregnant Women

Use ultrasound or MRI rather than CT for imaging to avoid fetal radiation exposure 5. Treatment principles remain the same, though aminoglycosides should be used cautiously.

Kidney Transplant Recipients

Prolonged combination therapy (21-27 days) with imipenem/cilastatin plus gentamicin and/or colistin, followed by oral fosfomycin, has shown success 4. Consider trimethoprim-sulfamethoxazole if susceptibility emerges during treatment 4.

Therapeutic Drug Monitoring

Perform TDM when possible for polymyxins, aminoglycosides, or carbapenems in CPE infections (weak recommendation, very low quality evidence) 3. This is particularly important in:

• Critical illness
• Renal dysfunction or augmented renal clearance
• Bloodstream infections or severe sepsis
• When using narrow therapeutic index drugs (polymyxins, aminoglycosides)

Key Risk Factors to Document

Patients with CPE UTIs typically have:

• Recent hospitalization (within 180 days) 6
• Prior carbapenem exposure 6
• Urinary catheterization 6
• Transfer from other healthcare facilities 6
• Rural residence (in some regions) 6

These factors should guide empiric therapy decisions while awaiting susceptibility results.